

August 28, 2025

Company name	CellSource Co., Ltd.
Name of representative	Takashi Sawada, Representative Director and CEO
Securities code	4880, Tokyo Stock Exchange, Prime Market
Contact information for inquiries	Tomohiro Iga, Executive Officer and General Manager of Corporate Division Tel: +81-3-6455-5308

CellSource and Solallis Bio Enter into Comprehensive Business Alliance Agreement in the Regenerative Medicine Field

- Accelerating Solutions to Regenerative Medicine Challenges and Promoting Social
Implementation through the Integration of Innovative Technologies and Clinical Expertise -



CellSource Co., Ltd. (Head Office: Shibuya-ku, Tokyo; Representative Director & CEO: Takashi Sawada, hereinafter referred to as "CellSource") and Solallis Bio Inc. (Head Office: Soraku-gun, Kyoto; Representative Director: Noriyasu Ishikawa, hereinafter referred to as "Solallis Bio") entered into a comprehensive strategic business alliance agreement effective July 22, 2025.

Solallis Bio has successfully commercialized the world's first cell preservation solution that enables cryopreservation without organic solvents, launching sales in May this year. This solution is characterized by its high safety and biocompatibility, as it places less stress on cells compared to conventional cryopreservation solutions. Solallis Bio also develops and sells culture media free of any animal-derived components, achieving stable cell quality and high safety.

Meanwhile, CellSource, which operates in the regenerative medicine field, has partnered with over 2,000 medical institutions across Japan. The company has a cumulative record of over 110,000 processing samples at its own authorized facility for specific cell processing and has accumulated extensive expertise by developing and providing services tailored to the diverse needs of clinical sites and patients.

Through this alliance, Solallis Bio's innovative technology and CellSource's practical know-how will be integrated enabling the development of products closely aligned with clinical needs. By leveraging their respective strengths, both companies will advance technological innovation and enhance the quality of services in the regenerative medicine field, aiming to realize safer and more accessible regenerative medicine.

As a first step, CellSource will introduce Solallis Bio's advanced products and begin development to further improve the safety, quality, and efficiency of its processing services. In the long term, the companies will enhance collaboration in improving CellSource's cell processing services through joint development of key regenerative medicine products, such as cell cryopreservation solutions and culture media, and by establishing high-quality cell manufacturing processes.

Comments from Representatives

Takashi Sawada, Representative Director and CEO of CellSource Co., Ltd.

"This comprehensive business alliance with Solallis Bio marks a significant step forward in driving technological innovation and enhancing services in the regenerative medicine field. By leveraging our respective strengths, we aim to build a safe and high-quality cell manufacturing process. We also plan to strategically strengthen the technological development capabilities that CellSource will need in coming fiscal years through this alliance. By addressing real-world challenges and needs at the clinical site, we will co-create new value and facilitate the broader adoption of regenerative medicine in society."

Noriyasu Ishikawa, Representative Director of Solallis Bio Inc.

"At Solaris Bio, we have continually asked ourselves what technologies will be essential for the next generation of regenerative medicine and have developed proprietary technologies to tackle those challenges. I am truly delighted that our achievements to date will contribute, through CellSource, to the treatment of people suffering from illnesses. This comprehensive business alliance will forge closer ties with the clinical and cell processing sites than even before. Through this collaboration, we are determined to further advance our technology and boldly undertake new challenges to pioneer the next generation of regenerative medicine. We are fully committed to endeavor and will contribute to the growth of both companies as well as to a bright future for regenerative medicine."

CellSource Co., Ltd.

CellSource specializes in advancing the industrialization of regenerative medicine, providing services such as processing adipose-derived stem cells, synovial-derived stem cells, and blood, as well as offering regulatory compliance support to medical institutions engaged in regenerative medicine. Operating under a Specific Cell Processing Manufacturing License (Facility Number: FA3240004) in

accordance with the Act on the Safety of Regenerative Medicine, it has handled over 110,000 cell-related procedures. With a wealth of experience, it strives to offer reliable services to medical institutions and contribute to research and technological development.

Representative Chairman of the Board: Masayuki Yamakawa

Representative director and CEO: Takashi Sawada

Listed Market: Tokyo Stock Exchange, Prime Market (Securities Code: 4880)

Location: Shibuya Cast 11F, 1-23-21 Shibuya, Shibuya-ku, Tokyo

URL: <https://www.cellsource.co.jp/en/>

Solallis Bio Inc.

Founded in Kyoto in 2023 with the philosophy of "Delivering Japan's cutting-edge technology to the world and tackling diseases with no effective treatment," Aiming to make regenerative medicine a more accessible and familiar form of healthcare, Solallis Bio is dedicated to the research and development of reagents and culture technologies used in regenerative medicine. We launched the StemDesign brand to propose ideal cell conditions, offering the world's first organic solvent-free cell cryopreservation solution, ELSSA OSFree, and culture media with high proliferation performance. Furthermore, we develop custom reagents tailored to meet individual needs, including personalized liquid agent, catering to detailed requests that are often difficult for large corporations to accommodate.

Representative Director: Noriyasu Ishikawa

Location: Keihanna Plaza, Lab Building, 1-7 Hikaridai, Seika-cho, Soraku-gun, Kyoto

Established: January 26, 2023

URL: <https://solallisbio.com/>

Note: This translation is for reference purposes only and is not guaranteed to be accurate or complete.

In the event of any translation error or misunderstanding, the original Japanese version shall prevail.